Loading
IC
Intra-Cellular Therapies, Inc. Stock: price and insider trades · United States
Intra-Cellular Therapies, Inc.: what insiders have been doing
Intra-Cellular Therapies, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at Intra-Cellular Therapies, Inc. has published a filing in the past twelve months. The most recent one dates from 2 April 2025.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
160
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€164M
29 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$586.2M
Net income-US$64.3M-11.0% margin
Last declaration on 2 April 2025
Declarations160 total
21,307 shares@ US$132.0043.1% of flowCommon StockSEC:0000950170-25-049646:0
52,811 shares@ US$132.0059.7% of flowCommon StockSEC:0000950170-25-049627:0
48,238 shares@ US$132.0060.4% of flowCommon StockSEC:0000950170-25-049596:0
42,913 shares@ US$132.0060.4% of flowCommon StockSEC:0000950170-25-049593:0
945,235 shares@ US$132.0092.8% of flowCommon StockSEC:0000950170-25-049595:0
11,340 shares@ US$132.0055.3% of flowCommon StockSEC:0000950170-25-049636:0
131,512 shares@ US$132.0090.2% of flowCommon StockSEC:0000950170-25-049648:0
1,567 shares@ US$132.00100.0% of flowCommon StockSEC:0000950170-25-049830:0
190,000 shares0Common StockSEC:0000950170-25-047937:0
13,133 sharesCommon StockSEC:0000950170-25-036591:0
13,133 sharesCommon StockSEC:0000950170-25-036594:0
40,712 sharesCommon StockSEC:0000950170-25-036593:0
13,133 sharesCommon StockSEC:0000950170-25-036592:0
8,742 sharesCommon StockSEC:0000950170-25-032584:0
8,742 sharesCommon StockSEC:0000950170-25-032585:0
34,969 sharesCommon StockSEC:0000950170-25-032587:0
12,239 sharesCommon StockSEC:0000950170-25-032586:0
7,009 shares@ US$63.794.4% of flowCommon StockSEC:0000950170-25-028030:0
11,017 shares0Common StockSEC:0000950170-25-013749:0
30,847 shares0Common StockSEC:0000950170-25-013765:0
11,017 shares0Common StockSEC:0000950170-25-013762:0
11,017 shares0Common StockSEC:0000950170-25-013763:0
215 shares@ US$83.520.1% of flowCommon StockSEC:0000950170-25-001440:0
51,000 shares@ US$12.730.5% of flowCommon StockSEC:0000950170-24-134240:0
22,869 shares@ US$23.948.6% of flowCommon StockSEC:0000950170-24-127275:0
25 of 160 declarations
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a US-based biopharmaceutical company listed on NASDAQ in the United States and focused on central nervous system disorders, with a specialty in discovering, developing, and commercializing innovative psychiatric therapies. The company is headquartered in Bedminster, New Jersey. Its scientific roots are tied to intracellular signaling research, and its commercial identity is now anchored by its lead asset, CAPLYTA® (lumateperone). ([intracellulartherapies.com](https://www.intracellulartherapies.com/Contact-us/?utm_source=openai))
The company’s business model is currently driven by CAPLYTA, an atypical antipsychotic approved in the US for schizophrenia in adults and for bipolar depression in adults. In addition, Intra-Cellular Therapies has pursued a supplemental filing for adjunctive treatment of major depressive disorder, which could significantly broaden the product’s addressable market if approved. Its 2024 results showed strong commercial momentum, with CAPLYTA net product sales rising materially year over year, underscoring improving market penetration and effective execution in a highly specialized therapeutic area. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1567514/000119312525031355/d923815dex991.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, the company occupies an attractive but highly competitive niche in specialty psychiatry. Its differentiation comes from a clinically established lead product and a pipeline that includes non-lumateperone programs such as ITI-1284, ITI-214, and ITI-1500. This gives the business both near-term commercial leverage and longer-term pipeline optionality. In neuropsychiatry, where tolerability, efficacy, and prescriber familiarity matter greatly, a differentiated profile can be a meaningful advantage, but sustained growth still depends on label expansion, physician adoption, and payer access. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1567514/000119312525031355/d923815dex991.htm?utm_source=openai))
Recent milestones have been important for the investment case. The FDA accepted the company’s supplemental NDA for CAPLYTA in adjunctive MDD, while 2024 sales growth confirmed the product’s commercial trajectory. The company also expanded its sales effort to support a potential broader launch. A major corporate development is that Johnson & Johnson completed its acquisition of Intra-Cellular Therapies on April 2, 2025, which materially changes the ownership and strategic context of the asset. For investors, the key questions are now centered on CAPLYTA’s continued franchise expansion, the regulatory path for additional indications, and how the neuropsychiatric platform is ultimately integrated within a global pharmaceutical portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1567514/000119312525031355/d923815dex991.htm?utm_source=openai))
